- Home
- ADI vs NVO Comparison
ADI vs NVO Comparison
Compare ADI & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADI | NVO |
|---|---|---|
| Founded | 1965 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0B | 208.2B |
| IPO Year | 1994 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ADI | NVO |
|---|---|---|
| Price | $384.64 | $46.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 11 |
| Target Price | ★ $385.45 | $51.00 |
| AVG Volume (30 Days) | 3.7M | ★ 11.3M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | 1.13% | ★ 3.19% |
| EPS Growth | ★ 39.02 | N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $6,200,942,000.00 | N/A |
| Revenue This Year | $28.41 | N/A |
| Revenue Next Year | $10.25 | $3.70 |
| P/E Ratio | $93.21 | ★ $13.60 |
| Revenue Growth | ★ 21.41 | N/A |
| 52 Week Low | $223.47 | $35.12 |
| 52 Week High | $449.52 | $64.16 |
Technical Indicators
Market Signals| Indicator | ADI | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 43.25 |
| Support Level | $375.59 | $45.62 |
| Resistance Level | $404.53 | $46.92 |
| Average True Range (ATR) | 10.83 | 1.37 |
| MACD | 2.32 | -0.27 |
| Stochastic Oscillator | 71.19 | 26.79 |
Price Performance
Historical ComparisonAbout ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.